Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME

Eur J Pharmacol. 2019 Oct 15:861:172593. doi: 10.1016/j.ejphar.2019.172593. Epub 2019 Aug 8.

Abstract

We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days) as a particular NO-system disturbance, and therapy possibilities. We demonstrated that it may be attenuated by subsequent administration of the NOS substrate L-arginine (100 mg/kg/day intraperitoneally), aggravated by NOS-blocker L-NAME (5 mg/kg/day intraperitoneally), all influenced by the stable gastric pentadecapeptide BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally or perorally, in drinking water). Regularly, cyclophosphamide dose- and time-dependently induced severe hemorrhagic cystitis lesions, gross lesions, and corresponding urothelial necrosis, vesical edema, erosion, hemorrhage, inflammation, and ulceration, microscopically. The bladder wet weight dramatically increased. Functionally, already after first cyclophosphamide administration, there is an increased leak point pressure. Until the second cyclophosphamide administration, L-arginine consistently attenuated regular cyclophosphamide-induced severe hemorrhagic cystitis lesions, grossly and microscopically, but not functionally. L-NAME aggravated these lesions and eradicated beneficial effect of L-arginine when combined. BPC 157 administration after cyclophosphamide, given in either dose or in either regimen markedly attenuated all cyclophosphamide lesions, grossly, microscopically. The increase of the bladder wet weight was consistently attenuated. Functionally, increased leak point pressure was reversed to the values noted in normal rats. The similar findings were noted in rats that received BPC 157 together with L-NAME or L-arginine, given alone or combined. Thus, the lesions are NO-related based on the administration of L-NAME as well as administration of L-arginine, and their mutual interaction, and counteraction by BPC 157 application. Likewise, we reveal new therapeutic possibilities, emphasizing stable gastric pentadecapeptide BPC 157 and L-arginine, versus L-NAME in rats underwent cyclophosphamide-induced cystitis.

Keywords: BPC 157; Cyclophosphamide; Hemorrhagic cystitis; NO-System; Rats.

MeSH terms

  • Animals
  • Anti-Ulcer Agents / pharmacology
  • Anti-Ulcer Agents / therapeutic use
  • Arginine / pharmacology*
  • Arginine / therapeutic use
  • Cyclophosphamide / adverse effects*
  • Cystitis / complications*
  • Cystitis / drug therapy*
  • Female
  • Hemorrhage / complications*
  • NG-Nitroarginine Methyl Ester / pharmacology*
  • NG-Nitroarginine Methyl Ester / therapeutic use
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Proteins / pharmacology*
  • Proteins / therapeutic use
  • Rats
  • Rats, Wistar

Substances

  • Anti-Ulcer Agents
  • Peptide Fragments
  • Proteins
  • BPC 157
  • Cyclophosphamide
  • Arginine
  • NG-Nitroarginine Methyl Ester